We currently are charging about 40% of the total cost for a drug review, and that's based on 100% time-tracking. So we know the costs are quite activity based—they're not just a guess. We charge about 40% of the true cost of a drug review right now.
As to the total revenues for the department, between us and one of our counterparts that does the post-market compliance and enforcement, I believe we raise about—is it $90 million?